# Gamma-delta T cells

Source: https://onco.cc/terms/gamma-delta-t-cells/  
OnCo record `gamma-delta-t-cells` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Gamma-delta T cells are a family of T cells whose receptor is built from different protein chains than most T cells, and different subsets recognise different signals, often without the usual peptide display. The family name does not say which signal a particular cell, or an engineered product, uses to find a tumour.

## Summary

The T-cell receptor of most T cells has alpha and beta chains; gamma-delta T cells have gamma and delta chains and also carry other activating and inhibitory receptors. They remain T cells and are distinct from natural killer cells. A review distinguishes gamma-delta from alpha-beta T cells partly by the antigens their receptors recognise, and notes that NKG2D is expressed by many gamma-delta subsets as well as by natural killer cells and CD8 T cells (Vantourout and Hayday, 2013). Names such as Vδ1 and Vγ9Vδ2 describe receptor variable regions and mark subsets that sit in different places. Healthy human breast tissue harboured a distinct gamma-delta compartment made mainly of Vδ1 cells, whereas Vδ2 cells predominate in blood; the breast Vδ1 cells could be activated innately through the NKG2D receptor, and in paired samples from 11 people with triple-negative breast cancer, progression-free and overall survival correlated with Vδ1 representation but not with total gamma-delta or Vδ2 cells (Wu et al., 2019). That is a small observational association in tissue biology and did not test an infused product.

## Fields

- Kind: Term
- Last checked: 2026-11-14
- Also known as: γδ T cells; gamma delta T cells

## Notes

- Recognition differs by subset, and it is not always free of HLA. For the Vγ9Vδ2 subset, which responds to phosphoantigens (small phosphorylated metabolites produced by microbes and overexpressed by some cancers), butyrophilin 2A1 (BTN2A1) binds the Vγ9 chain of the receptor, associates with a second butyrophilin, BTN3A1, and the two act together to start the response; a second ligand, possibly BTN3A1, binds a separate region that includes the Vδ2 chain (Rigau et al., 2020). This is not a peptide sitting in an HLA groove. HLA independence is also not universal: one characterised Vγ5Vδ1 receptor was restricted by HLA-A*24:02 and depended on the CD8-alpha co-receptor, acting on blood-cancer and solid-tumour cells in vitro and in vivo while sparing healthy tissue in those models (Kierkels et al., 2019). That receptor's mechanism is not an eligibility rule for the family.
- An engineered receptor is a separate recognition route. Adding a GD2-directed chimeric antigen receptor to expanded human Vδ1 and Vδ2 cells increased GD2-specific killing of GD2-expressing cancer cell lines, did not impair movement towards tumour cells in vitro, and expanded Vδ2 cells kept the ability to take up tumour antigen and cross-present it to alpha-beta T cells (Capsomidis et al., 2018). That is a preclinical result for that preparation, and it does not show that any gamma-delta product enters tumours, cross-presents usefully or prevents antigen escape in patients. An allogeneic gamma-delta product that the registry names HLA-G-CAR.BiTE allogeneic γδ T cells (NCT06150885, phase 1 and 2) was listed as recruiting when the registry record was read for this entry; the record describes the product and the study design and reports no efficacy. A receptor added to a cell needs its own target on the tumour, HLA-low does not mean target-positive, and avoiding peptide presentation is not the same as avoiding antigen escape. Cells are identified by flow cytometry and receptor sequencing, but a response against one target line does not establish tumour entry, persistence or benefit, and matched cells without the added receptor are needed to separate native from engineered recognition. Two cautions are OnCo's reasoning and not findings of the cited papers: a product made of many receptor clones is not automatically broader or more effective than one defined clone, and the name gamma-delta describes the receptor chains and not the cell source, so whether cells came from the patient or from a donor has to be stated separately.
- Measurement separates identity, repertoire and function. Sanz et al. (2023) used flow cytometry to isolate human gamma-delta subsets and assessed receptor repertoires separately from cytotoxicity. Their Daudi-cell cocultures included target-only and effector-only controls; degranulation, granzyme or perforin measurements and target-cell death were distinct readouts. These are results for defined human subsets and laboratory targets, not a universal assay or a test of tumour entry in patients.
- For interpretation, report the parent population, percentage and any valid absolute count with the specimen and sampling method. Receptor-sequence abundance does not identify the receptor ligand. Rigau et al. (2020) established a defined BTN2A1-dependent recognition mechanism for the Vgamma9Vdelta2 phosphoantigen response; that specificity is an example of why innate-like does not mean nonspecific. To test native versus added-receptor recognition, compare matched cells without the added receptor, target-positive and target-negative cells, and a suitable receptor-blocking or target-perturbation condition. Keep relevant healthy-cell controls, viability and exposure conditions explicit. This is experimental-design reasoning from the separate recognition mechanisms, not a claim that one cited assay validates every product. HLA loss does not establish that the native ligand or the added receptor target is present, and two recognition routes do not prove escape prevention.
- The gamma-delta T-cell receptor, NKG2D and DNAM-1 are different receptors. BTN2A1 binds the Vgamma9 receptor chain and works with BTN3A1 in the specified phosphoantigen response; the BTN names do not name the T-cell receptor itself. Reviewed human UniProt entries distinguish NKG2D ligands, including MICA, MICB and ULBP proteins, from the DNAM-1/CD226 ligands CD155/PVR and CD112/NECTIN2. These receptor-ligand associations do not establish that every gamma-delta subset expresses or uses each route. Check the actual cell preparation and keep ligand identity, receptor expression and controlled target-cell killing separate.
- Phosphoantigen sensing and the T-cell receptor contact occur on different sides of the target-cell membrane. Sandstrom et al. (2014) showed that phosphoantigens bind the intracellular B30.2 domain of BTN3A1. Yuan et al. (2023) reported that phosphoantigens promote association between the intracellular domains of BTN3A1 and BTN2A1; mutations that hindered the association blocked the tested Vgamma9Vdelta2 activation. These are target-cell sensing events, rather than free metabolites occupying a peptide-HLA groove, and they concern a defined phosphoantigen response rather than every gamma-delta subset. Rigau et al. (2020) described an additional receptor interaction with a tentative second ligand. That is the study's historical interpretation; a dashed extra contact in a simplified sketch does not specify a complete atomic structure. An added CAR still needs its own surface target, and neither a native metabolic signal nor loss of classical HLA establishes that target's presence.

## Sources

- Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells.: https://doi.org/10.1126/science.aay5516
- Identification of a tumor-specific allo-HLA-restricted γδTCR.: https://doi.org/10.1182/bloodadvances.2019032409
- An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer.: https://doi.org/10.1126/scitranslmed.aax9364
- Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation.: https://doi.org/10.1016/j.ymthe.2017.12.001
- ClinicalTrials.gov NCT06150885: https://clinicaltrials.gov/study/NCT06150885
- Six-of-the-best: unique contributions of γδ T cells to immunology.: https://doi.org/10.1038/nri3384
- Sanz et al., 2023: Deep characterization of human gamma-delta T cell subsets: https://doi.org/10.3389/fimmu.2023.1148988
- UniProt Q15762: reviewed human CD226/DNAM-1 function: https://www.uniprot.org/uniprotkb/Q15762/entry
- UniProt P26718: reviewed human KLRK1/NKG2D function: https://www.uniprot.org/uniprotkb/P26718/entry
- The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells.: https://doi.org/10.1016/j.immuni.2014.03.003
- Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate Vγ9Vδ2 T cells.: https://doi.org/10.1038/s41586-023-06525-3

## Connected records

- technologies: [Gamma-delta T cell therapy](https://onco.cc/technologies/gamma-delta-t-cell-therapy/)
- terms: [Immune system](https://onco.cc/terms/immune-system/), [NK cell](https://onco.cc/terms/nk-cell/), [T cell](https://onco.cc/terms/t-cell/)
- trials: [A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors](https://onco.cc/trials/nct06150885/)

---
JSON: https://onco.cc/api/v1/entities/gamma-delta-t-cells.json